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Summary
Objective: To develop and characterize a polyclonal antiserum (RAM 3.2), which recognizes the neo-C terminal cleavage product generated
by the action of aggrecanase (ADAMts 4/5) on the G1-domain of human aggrecan. We also intend to use this antiserum to investigate
normal, age-related changes in human articular cartilage.
Method: The antiserum was raised in rabbits and its localization in cryosections of normal articular cartilage was investigated by
immunohistochemistry. The concentration of the aggrecanase neo-epitope was also investigated in extracts of the tissue using SDS-PAGE
and electrophoresis in large pore/agarose gels.
Results: The product of aggrecanase action appears to accumulate in the extracellular matrix during normal aging of the tissue. Furthermore,
the concentration of the fragment depended on the topographical site on the femoral condyle from which the sample was selected.
Electrophoretic and immunohistochemical analysis of the fragment in normal cartilage showed that in immature cartilage it was deposited
mainly in the surface layers, whereas in mature samples it was distributed throughout the depth of the tissue. In contrast, immunoreactivity
of osteoarthritic cartilage was always less and the distribution was more variable than in normal cartilage of the same age.
Conclusions: (1) The proteolytic cleavage of aggrecan by aggrecanase is a normal homeostatic event and much of the neo-C terminal
fragment produced by the enzyme is retained in the tissue. (2) The presence of this immunoreactive product in normal cartilage can be used
as an indication of aggrecan turnover. (3) That in osteoarthritic cartilage there is a reduction in the concentration of the G1-fragments.
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Articular cartilage is an aneural, avascular and acellular
tissue. The principal components of the extracellular matrix
are type II collagen fibres which form a fibrous network that
provides tensile strength and a high concentration of the
large, hydrophilic aggregating proteoglycan, aggrecan,
which hydrates the collagen network giving cartilage its
viscoelastic properties and the ability to resist mechanical
compression1. Aggrecan is composed of a central protein
core containing three globular domains. Two of the
domains (G1 & G2) are located at the amino terminus of
the protein and are separated by a short extended seg-
ment, the interglobular domain (IGD). This organization
immobilizes the aggrecan molecule within the cartilage
matrix and the interaction is stabilized in situ by link
protein2. The water imbibing, chondroitin sulfate and kera-
tan sulfate chains associated with aggrecan are covalently
linked to an extended C-terminal portion of the core protein.553Thus, cleavage in the IGD will result in a loss of the
glycosaminoglycan-rich region of aggrecan and, as a
consequence, the viscoelastic properties of the tissue.
During normal aging of articular cartilage there is a
decrease in the total water content of the tissue and many
post-translational modifications of aggrecan are observed,
such as changes in the pattern of glycosylation and sulfa-
tion of glycosaminoglycan chains. For example, the distri-
bution and length of the keratan sulfate chains increases
with age, whereas, there is a corresponding decrease in
the chondroitin sulfate content and the di-4S:di-6S
ratio3,4. These changes are consistent with a model of
aggrecan turnover that implicates selective proteolytic deg-
radation of the glycosaminoglycan-rich region of the mol-
ecule and the accumulation of partially degraded aggrecan
in the extracellular matrix5. This process of proteolysis can
also occur within the IGD during normal turnover of aggre-
can and the G1-fragment generated, the ‘free’ G1-domain,
can account for up to 50% of the total G1 concentration in
the tissue. Our recent studies support this model of aggre-
can degradation and the aging of cartilage matrix, by
showing that the ‘molecular age’ of the ‘free’ G1-domain is
25 years in adult human cartilage, whereas, that of the
intact aggrecan molecule from the same tissue is only 3.5
years6.
Numerous studies have been carried out in order to
define the proteinase(s) involved in aggrecan turnover in
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novel proteolytic activity, aggrecanase (ADAMts 4/5), is
one of these enzymes7,8. This activity is defined by the
specific cleavage of the aggrecan molecule in the IGD
resulting in fragments with the neo-C-terminal sequence
G1-NITEGE-COOH and neo-N-terminal sequence
NH2ARGSV-G2. Products of aggrecanase cleavage were
first identified in culture medium from bovine articular
cartilage and the G1-NITEGE-COOH neo-epitope has
since been demonstrated in human articular cartilage
where an age-related increase in its concentration was
observed9. Furthermore, fragments of aggrecan released
into human synovial fluid after knee injury and in osteoar-
thritis (OA), rheumatoid arthritis (RA), reactive and psoriatic
arthritis as well as acute calcium pyrophosphate dihydrate
deposition disease have been characterized and appear to
result from the same proteolytic cleavage10.
The present study describes the characterization of an
antiserum that specifically reacts with the carboxy terminal
neo-eopitope generated by aggrecanase cleavage of the
IGD of human aggrecan and illustrates the spatial, topo-
graphical and age-related distribution of this epitope within
normal human articular cartilage.Materials and methods
MATERIALS
All reagents were of analytical grade (BDH Chemicals,
Poole, Dorset, U.K.). Guanidine hydrochloride, 6--caproic
acid, benzamidine HCl, phenylmethanesulphonyl fluoride,
DAB and anti-rabbit IgG antibody peroxidase conjugate
were obtained from Sigma Chemical Co. (Poole, Dorset,
U.K.). Chondroitinase ABC was from ICN Pharmaceuticals
Ltd., (Oxon, U.K.). Keratanase and keratanase II were from
Seikagaku, Kogyo Co. Ltd (Tokyo, Japan). Donkey bioti-
nylated anti-rabbit Ig, Streptavidin-HRP, Hybond-N+
membrane, reagents for enhanced chemiluminescence
(ECL) and Hyperfilm-MP were obtained from Amersham
International Plc,. (Little Chalfont, U.K.). Nitrocellulose
(0.2 m) was from Schliecher and Scheull.SYNTHESIS AND CHARACTERIZATION OF THE PEPTIDES
In choosing the sequences for antiserum generation we
took into account, (1) the antigenicity of the peptides as
determined for soluble globular proteins, (2) the unique-
ness of the proposed peptide epitope and, (3) the structure
of the aggrecan cleavage site. The average antigenicity
index for the neo-carboxy terminal peptide H-
GCPLPRNITEGE-OH was 0.805 while that for the neo-
amino terminal peptide, H-ARGSVILTVK-OH was −0.80.
These antigenicity values suggest that the neo-carboxy
terminal would be antigenic, while the non-polar nature of
the VILTV segment in the neo-amino terminal makes it a
poor antigen. This probably explained our inability to gen-
erate antibodies to the latter peptide. For this study three
peptides were synthesized, (1) the neo-amino terminal
peptide generated upon aggrecanase cleavage of
aggrecan, H-ARGSVILTVKCG-OH; (2) the neo-carboxy
terminal peptide H-GCPLPRNITEGE-OH, and (3) a
peptide that spanned the aggrecanase cleavage site
H-RNITEGEARGSVCL-OH. The amino acids in italics are
not found in the native aggrecan molecule and were
included so that the penultimate cysteine could be used as
a defined conjugation site. The peptides had molecularformulae of C53H88N16O19S, C51H94N16O15S and
C60H105N21O22S and chemical mass of 1285.45, 1203.48
and 1504.7, respectively. Peptide composition was con-
firmed using laser desorption mass spectrometry where
peptides 1, 2 and 3 had (M+H)+ Acc mass of 1285.5,
1204.9 and 1504.2 respectively. The peptides’ purity was
checked by RP-HPLC on a Vydac 218TP54 C18 column
using a 10–40% Acetonitrile:H2O (+0.1% TFA) gradient run
at 1 ml/min and 50°C.ANTIBODY PRODUCTION
Peptides were conjugated via the free cysteine to oval-
bumin, BSA and/or KLH using standard protocols. They
were injected into rabbits at 100 g of peptide as follows:
week 0 injection in Freunds complete (1:1); weeks 4 and 8
injection in Freunds incomplete. Test bleeds were taken at
6 and 10 weeks. Reactivity was tested in pre-immune
serum (RAM 3.0) and test-bleeds using standard ELISA
technique as follows. ELISA-plate wells were coated with
the peptide conjugates (100 g/well in carbonate/
bicarbonate buffer, pH 9.6). After blocking the ELISA plate
with PBS-Tween-1% Marvel solution, serial dilutions of
pre-immune or test bleed serum, from 1/10 to 1/100,000 in
PBS-Tween-1% Marvel, were applied. The antibody was
indirectly detected using antirabbit IgG peroxidase conju-
gate (1/2000 in PBS-Tween-1% Marvel) with the peroxi-
dase substrate OPD using standard protocols. Absorbance
was measured using a Titertek plate reader.PREPARATION OF ARTICULAR CARTILAGE EXTRACTS
Articular cartilage ranging in age from 5–65 years was
obtained from mid-thigh and hindquarter amputations at the
time of surgery; it was macroscopically normal and was
also assessed histologically in order to determine that it
had an intact articular surface. Fetal cartilage was obtained
from the knee joints of full-term fetuses within 12 h of death.
Ostoeoarthritic cartilage was obtained at the time of sur-
gery for total knee replacement and, therefore, represented
cartilage at the end of the disease process. Cryosections
(20 m) of cartilage were extracted with 4 M guanidine HCl,
0.05 M sodium acetate buffer, pH 6.8 at 4°C for 24 h.
Insoluble debris was removed by filtration. Supernatants
containing the protein preparations were dialysed into
0.05 M sodium acetate, pH 6.8 and stored at −20°C in
small aliquots. All extraction and dialysis buffers of cartilage
in the preparative procedures contained proteinase inhibi-
tors (0.01 M disodium EDTA, 0.1 M 6--caproic acid,
0.005 M benzamidine HCl, 0.0005 M phenylmeth-
anesulphonyl fluoride). Through the depth studies were
carried out by taking 4 mm diameter cores of cartilage from
sites on the femoral condyle or the tibial plateau. Each core
was sectioned at 50 m from the articular surface, pooling
every four sections through the tissue depth, in order to
assess zonal variations. The pooled sections were
extracted, digested with chondroitinase ABC and keratan-
ase and separated by SDS-PAGE. Western blots of these
gels were analysed as described above.DIGESTION WITH ENZYMES
Aggrecan prepared from bovine nasal cartilage (A1D1)
fraction was digested with cathepsins B (12.5–
50.0 pmoles/ml) of cathepsin L (1,25–5.0 pmoles/ml), both
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carried out in 88 mM KH2PO4/12 mM Na2HPO4 buffer,
containing 1 mM Na2EDTA, 10 mM cysteine, 0.01% Brij 35
for 15 h at 37°C. Plasmin (Boeringher) digestion of aggre-
can was performed using 2 mg/ml plasmin in 100 mM Tris
HCl, pH 7.4 and digested at 37°C for 0–20 h.
Media from IL-1 treated bovine nasal cartilage was used
as a source of aggrecanase cleaved G1-domain. This
media was buffered with 50 mM Tris HCl, pH 7.4 and
carboxy peptidase B was added to 0.625 mg/ml and diges-
tion was at 37°C for 0–3 h. In all cases the reaction
was stopped by the addition of urea to 4 M and
2-mercaptoethanol to 5%. The samples were immediately
electrophoresed in composite gels or stored frozen at
−20°C until required for analysis.AGAROSE/POLYACRYLAMIDE COMPOSITE GEL ELECTROPHORESIS
AND WESTERN BLOTTING
Samples containing 3 g uronic acid were dialysed
against deionized distilled water, lyophilized and reconsti-
tuted in 8 M urea for 16 h. Samples were electrophoresed
in 1.2% acrylamide/0.6% agarose gels which had been
equilibrated for 16 h in 4 M urea/10 mM Tris acetate/
0.25 mM sodium sulfate pH 6.8 at 4°C, as outlined by
Carney et al.11. Total proteoglycans were stained with
toluidine blue (0.2% w/v in 0.1 M acetic acid) for 20 min; the
gels were destained in 3% acetic acid. Samples were
electrophoretically transferred (Towbin et al.) onto Hybond-
N+ nylon membranes for 2 h at 80 mA at 4°C using a
Bio-Rad wet blotter in 10 mM Tris acetate/0.25 mM sodium
sulfate, pH 6.8. The membranes were incubated overnight
at 4°C in PBS containing 5% Marvel and then digested for
3 h at room temperature with 0.025 U chondroitinase ABC,
0.025 U keratanase and 0.0025 U keratanase II in 50 mM
sodium acetate, pH 7.4. Washes were carried out in PBS
containing 1% Marvel for 1 h, followed by incubation
for 1 h with the primary antibody diluted 1 in 1000 and then
with a horseradish peroxidase-conjugated secondary
antibody diluted 1 in 5000 (Sigma Chemical Co.) The
immunoreactive bands were detected by enhanced
chemiluminescence, according to the manufacturer’s
instructions.SDS-PAGE AND WESTERN BLOTTING
Samples containing 6 g uronic acid were dialysed into
deionized distilled water, lyphilized and then digested for
2 h at 37°C with chondroitinase ABC, keratanse and kera-
tanase II as described above. Digests were reduced with
5% 2-mercaptoethanol and electrophoresed in 5–15%
polyacrylamide gradient slab gels. Proteins were electro-
phoretically transferred onto nitrocellulose for 16 h at
80 mA at 4°C and the membranes were incubated for 1 h
inPBS containing 5% Marvel. Washes and incubations with
primary and secondary antibodies and ECL detection were
as described for agarose/acrylamide composite gels.IMMUNOLOCALIZATION
Immunohistochemical studies entailed floating 8 mm
thick frozen sections onto gelatin-coated slides and allow-
ing them to air dry. The sections were sequentially incu-
bated with RAM 3.2 (diluted 1 in 20,000), a biotinylatedsecondary antibody, streptavidin-conjugated horseradish
peroxidase and DAB. The DAB deposits were then silver
enhanced using a kit from Amersham International Plc.
Pre-immune serum was used as a negative control.Fig. 1. ELISA of the immune and pre-immune, KLH -linked peptide
GCPLPRNITEGE. Only the antibody raised against this neo-C
terminal amino acid sequence, generated by degradation of the
G1-domain of aggrecan by aggrecanase, reacted in the assay.
() Immune serum; () preimmune serum.Results
CHARACTERIZATION OF THE ANTISERUM
A peptide (NITEGE) was synthesized that corresponded
to the neo-carboxy terminal sequence of the IGD generated
by the action of aggrecanase. This was linked to KLH or
ovalbumin and rabbits were immunized with the conjugated
peptides. ELISA results showed that the KLH-NITEGE
peptide antiserum (RAM 3.2) specifically bound the peptide
conjugate (Fig. 1). No immunoreaction was observed using
a peptide conjugate that spanned the cleavage site or had
an irrelevant amino acid sequence. Antibodies were
observed after the first test bleed, however, with further
injections the titre decreased. This was more apparent
when the peptide was conjugated with ovalbumin than
when it was attached to KLH. No reaction was observed
with the pre-immune sera.
To determine whether the RAM 3.2 antiserum reacted
with the native protein, aggrecanase-cleaved G1 was pre-
pared by treating bovine nasal cartilage with interleukin 1
[Fig. 2(a),(b)]. The culture media was analysed using
agarose-polyacrylamide composite gels and an immuno-
reactive protein was observed which migrated slower than
the toluidine blue-stained (glycosaminoglycan containing)
fragments [Fig. 2(a),(b), lane 10]. However, intact aggrecan
did not react with the antiserum [Fig. 2(a),(b), lane 1]. When
the culture medium from IL-1-treated bovine nasal cartilage
was digested with carboxypeptidase B, a time-dependent
loss of immunoreactivity was observed [Fig. 2(b), lanes
2–8]. The accompanying toluidine blue stained bands
(glycosaminoglycan-rich aggrecan fragments) also in-
creased their rate of migration as the digestion proceeded
[Fig. 2(a)]. This experiment confirmed that the antiserum,
RAM 3.2, only recognized the neo-carboxy terminal end of
the G1-fragment.
We then determined whether RAM 3.2 could recognize
alternative proteinase cleavage sites that were close to the
aggrecanase cleavage site (Glu373-Ala374). Intact aggrecan
was digested with plasmin, cathepsin B or cathepsin L
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carboxypeptidase B digested culture medium, obtained from IL-1
treated bovine nasal cartilage. The enzyme (lanes 2–9) reduced
both the (a) Toluidine blue staining and (b) the immunoreactivity of
the culture medium. Intact aggrecan (lane 1) did not react with
RAM 3.2, but medium from IL-1 treated bovine nasal cartilage,
did react (lane 10).Fig. 3. The effect of age on immunoreactive products in normal
human articular cartilage. Normal human articular cartilage of
different ages (lanes 1–8=fetal, 5 years, respectively) was
extracted with 4M-GnHCl and the dialysed extracts were subjected
to SDS-PAGE and a Western blot was probed with RAM 3.2.
Lanes 1–3 showed only a very low intensity of reactivity with RAM
3.2 after longer exposure of the Western blot.Fig. 4. Age-related changes in the structural heterogeneity of
human aggrecan. Agarose/PAGE of normal human cartilage
extracts (lanes 1–8). (a) Toluidine blue stained gel; (b) Western blot
probed with an antiserum recognizing the G1 domain of human
aggrecan; (c) Western blot probed with the antiserum RAM 3.2.
The aggrecanase-generated G1 domain that was RAM 3.2 posi-
tive appeared to be present at higher concentrations in the extracts
of adult cartilage.which should result in cleavage at the Gly375–Ser376,
Gly344–Val345, and Ala690–Ala691 bonds respectively, i.e.
not the aggrecanase cleavage site. When the digests were
separated by gel electrophoresis and the gel was stained
with toluidine blue these proteinases did degrade aggre-
can, but no immunoreactive material was generated
(results not shown). These results confirmed that RAM 3.2
did not recognize the neo-epitope sequence generated by
the action of these known proteinases.DISTRIBUTION OF RAM 3.2 REACTIVE PRODUCTS IN NORMAL
CARTILAGE
In order to determine the molecular weight of the RAM
3.2 immunoreactive material, samples from a range of ages
were separated by SDS-PAGE (Fig. 3) and a ∼65 kDa band
was identified in each case. A higher molecular weight band
was also recognized in the 21-year-old and 31-year-old
specimens, and may represent a doublet of the G1-domain;
however, we have not investigated this further. A high
concentration of immuno-reactive material was present in
the 21-year-old, 31-year-old and 65-year-old samples of
cartilage. Extracts of normal articular cartilage of different
ages were also fractionated in composite, agarose/
polyacrylamide gels. An age-related increase in molecular
heterogeneity was observed when the gels were stained
with toluidine blue [Fig. 4(a)]. Probing of a Western blot of
the same extracts with an antiserum recognizing human
G1-domain, confirmed that all three toluidine blue-staining
bands were intact aggrecan [Fig. 4(b)]. In addition, a slower
migrating diffuse band was also observed, this reacted with
the RAM 3.2 antiserum and was present at very high
concentrations in the 21-year-, 31-year- and 65-year-old
specimens, i.e. some of the protein in this band was
generated by the action of aggrecanase [Fig. 4(c)]. Wehave now analysed a large number of normal cartilage
specimens and can confirm that there is an age-related
increase in the RAM 3.2 positive fragment. Furthermore,
when these gels were loaded on the basis of original wet
weight of the sample instead of the uronic acid content,
the same result was obtained. It should also be noted
that none of the intact aggrecan species were RAM 3.2
immunoreactive.
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The topographical distribution of aggrecanase-
generated G1 fragment was studied by extracting cartilage
obtained from a number of different sites of a normal adult
(74 years) knee joint (Fig. 5). Analysis of the extracts by
SDS-PAGE indicated that the fragment was not evenly
distributed within the joint and that the highest concen-
trations were present at sites corresponding to the higher-
loaded regions of the femoral condyle and to the areas of
the tibial plateau covered by the menisci (Fig. 6). Sites 2, 5,
6, 9 and 10 contained the highest concentration of this
fragment.
In order to study the zonal distribution of the immunore-
active G1 fragment, full depth plugs of articular cartilage
were obtained from site 2 of knee joints aged 14 years, 43
years and 60 years and these were sectioned through the
depth at 50 m, pooling every four sections to give zones of
200 m. Analysis of the 14-year-old extracts showed that
RAM 3.2 positive material was confined to the surface layerof the tissue (Fig. 7). By 43 years of age the immunoreac-
tivity was very strong in the upper zones of the tissue and
had also extended into the deeper layers of the cartilage.
However, by 60 years of age the extracts from all layers of
the tissue were immunoreactive. These findings were sup-
ported by the analysis of zonal extracts from other speci-
mens of cartilage (data not shown). The gels have been
aligned so that it appears that the change in tissue thick-
ness occurs from the bottom of the tissue. However, this
could arise from a loss of the superficial layers of cartilage
and the reader should be aware of this.
Confirmation of the zonal distribution described above
and an analysis of the compartmental distribution (i.e.
pericellular, intracellular or interterritorial) of RAM 3.2
reactive material, was determined by immunohistochemical
studies of cryosections of cartilage. Figure 8 shows surface
and full-depth immunostaining of a 4-year-old and 53-year-
old specimen respectively. All of the immunostaining is
extracellular. Cartilage was also analysed at two regions of
an osteoarthritic condyle, from a 74-year-old subject. The
macroscopically normal region was thicker and RAM 3.2
positive reaction was no longer distributed throughout the
depth of the tissue, but was confined to a narrow zone just
below the articular surface. In contrast samples of cartilage
from a region which was thinner and fibrillated, had even
less immunoreactive material. Preincubation of the RAM
3.2 antiserum with the immunizing peptide, abolished the
immunoreaction of tissue sections (results not shown).Fig. 5. Schematic showing the areas of the femoral condyle and
tibial plateau of a normal knee joint, taken for the analysis
described in Fig. 6.Fig. 6. Localization of RAM 3.2 immunoreactivity within different
regions of a normal human knee joint. Extracts of human cartilage
were removed from the sites 1–10 described in Fig. 5 and
electrophoresed in SDS/polacrylamide gels. The Western blot of
the gel was probed with RAM 3.2 and this showed that the
immunoreactive fragment was not evenly distributed within the
tissue.Fig. 7. Zonal variation in the RAM 3.2 reactive fragment. Plugs of
cartilage from site 2 of three normal knee joints (14 years, 43 years
and 60 years) were sectioned through their depth (lanes 1–10)
before each layer of tissue was extracted with 4M-GnHCl. Western
blots of SDS/polyacrylamide gels were probed with RAM 3.2.
Immunoreactivity was confined to the surface of the tissue in the
immature cartilage, but was present throughout the tissue depth of
the mature specimens.Discussion
An anti-peptide serum (RAM 3.2) was prepared using a
peptide with the amino acid sequence, NITEGE, which
corresponds to the neo-carboxyl terminal of the G1-domain
that is generated when human aggrecan is cleavage by
aggrecanase. The antiserum was specific for this sequence
as demonstrated by its inability to recognize intact aggre-
can or other peptide sequences. Its immunoreactivity was
also blocked by pre-incubation with the immunizing pep-
tide. The antiserum was, therefore, used to investigate how
the age of the individual affects the distribution of this
G1-fragment in the tissue.
A number of other published studies have demonstrated
that aggrecanase is active in joint disease. For example,
558 M. T. Bayliss et al.: Aggrecanase cleavage products in articular cartilageFig. 8. Age-related variation in the immunohistochemical localization of RAM 3.2 reactive products. Frozen histological sections of 4-year-
and a 59-year- old normal human articular cartilage were exposed to the primary antiserum, RAM 3.2, as described in the Materials and
Methods Section. Only the upper half of the 4-year-old cartilage is shown. Two regions of osteoarthritic cartilage (74 years) were similarly
treated and immunoreactive fragments were localized using diaminobenzidine. Fragments of the G1 domain of aggrecan were present only
at the surface of normal immature articular cartilage, but were present throughout the depth of the adult specimen. A decreased
concentration of immunoreactive fragment was observed in the osteoarthritic cartilage.
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ments present in the synovial fluid of patients with a variety
of inflammatory and non-inflammatory joint diseases, had
the amino-terminal sequence 374ARGSVIL-, as a conse-
quence of the enzymatic action of aggrecanase. More
recently, Lark et al.9 also demonstrated that a considerable
proportion of the G1-domain remaining in the matrix of
normal and diseased articular cartilage was also a product
of aggrecanase action. Our findings, confirm and extend
these analyses by showing that this fragment of the
G1-domain accumulates in the tissue during aging of the
tissue. In this respect the results also agree with the recent
data published by Maroudas et al.6 which demonstrated
that the ‘molecular age’ of the ‘free’ G1-domain in adult
human cartilage was much greater than that associated
with intact aggrecan, i.e. it had a half life of 25 years
compared to 3.5 years for aggrecan.
The RAM 3.2 antiserum was also used to demonstrate
the heterogeneity of chondrocyte metabolism that exists in
articular cartilage. Thus, in normal immature cartilage the
G1-fragment accumulates in the upper regions of the tissue
and only with time, as the cartilage thins, does it accumu-
late in the deeper zones. If we assume that the same
proteolytic events are occuring in different regions of carti-
lage at a given age, then these results suggest that
although the cells in the upper zones of cartilage have a
low rate of proteoglycan synthesis12 their rate of proteo-
glycan degradation is occuring at a faster rate than those in
the deeper zones of the tissue, i.e. the rate of turnover of
the extracellular matrix is faster in the surface regions of the
cartilage. This observation is also consistent with the
expansion of the joint volume that must take place as
cartilage grows. Although this is an appealing hypothesis, it
should be appreciated that an immunohistochemical
approach only identifies the presence or absence of a
specific epitope. It may also be that the immunoreactive
fragment is not generated by the turnover mechanism that
is active in the deeper layers of immature cartilage, or that
there is a mechanism for rapidly removing it from the
hyaluronan chain so that it cannot be immunolocalized.
There is no evidence to support the former mechanism and
the low concentration of the total G1-domain measured in
normal immature cartilage, does not support the latter
one6. However, the loss of immunostaining in the osteo-
arthritic cartilage described here, does add credence to the
latter mechanism and unpublished studies carried out by
Bayliss have shown that osteoarthritic cartilage has a much
lower content of the ‘free’ G1-domain. There is, therefore, a
distinct possibility that a biological mechanism is activated,
when chondrocytes are ‘stressed’, which enables
additional binding sites on the hyaluronan chains in the
extracellular matrix to be exposed so that they can be
used for the attachment of intact aggrecan molecules.
Support or refutation of this hypothesis will require further
experimentation.
There are also many published studies indicating that
mechanical loading affects the metabolic activity of the
chondrocyte13,14. The experiment described in this paper
(Fig. 6) used the concentration of the aggrecanase-
generated G1-domain as a surrogate marker of this pro-
cess and showed that the turnover of aggrecan is probably
linked to the load applied in vivo to the cartilage. In this
respect the findings are not too surprising, but they do
emphasize how important it is to be certain that the same
topographical regions of the normal and abnormal joint are
compared in any experimental analysis that is carried out.In conclusion, the data make a number of important,
novel contributions to our knowledge of the turnover of
aggrecan in normal and diseased cartilage. Not least
among these is the finding that the metabolism of the
extracellular matrix by the chondrocyte is extremely vari-
able. Ignorance of this fact alone could lead to the design of
inappropriate experiments.Acknowledgments
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